Skip to main content
. Author manuscript; available in PMC: 2014 Jul 9.
Published in final edited form as: Biochem Pharmacol. 2012 Jun 21;84(5):701–711. doi: 10.1016/j.bcp.2012.06.010

Fig.1. Time course of DEC1 and CYP3A4 expression in primary human hepatocytes treated with IL-6.

Fig.1

(A) Time course of DEC1 mRNA level in human hepatocytes treated with IL-6. Human primary hepatocytes were treated with IL-6 (10 ng/ml) or the same volume of PBS for 24 h. Total RNA was isolated and subjected to qRT-PCR analysis for the level of DEC1 probe as described under Materials and Methods. The qPCR Cts were 25 for DEC1, and 20 for GAPDH. (B) Time course of DEC1 and CYP3A4 protein levels in human hepatocytes treated with IL-6. Human hepatocytes were treated with IL-6 (10 ng/ml) or the same volume of PBS for 48 h, and cell lysates were prepared and lysates (8 μg) were subjected to Western blot analyses with an antibody against DEC1, CYP3A4 or GAPDH (n = 5). All experiments were repeated at least three times, and data were expressed as mean ±SD. * p<0.05, statistically significant decrease by IL-6 treatment.